drugset / Trial / NCT07381699
MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial
NaSingle-groupOpen-labelTreatment
Summary
This study was designed to compare the efficacy and safety of Becotatug Vedotin (MRG003) combined with Pucotenlimab as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Timeline
- Start
- 2026-02-01
- Primary completion
- 2028-02-01
- Completion
- 2030-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Becotatug Vedotin | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Pucotenlimab | Monoclonal antibody | 200 mg | Intravenous |